MCID: PTT048
MIFTS: 57

Pituitary Adenoma, Prolactin-Secreting

Categories: Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Pituitary Adenoma, Prolactin-Secreting

MalaCards integrated aliases for Pituitary Adenoma, Prolactin-Secreting:

Name: Pituitary Adenoma, Prolactin-Secreting 57 12 13
Prolactinoma 12 53 59 75 55 44 15 73
Prolactin-Secreting Pituitary Adenoma 53 59 75
Prl-Secreting Pituitary Adenoma 53 59
Pituitary Lactotrophic Adenoma 53 59
Prolactinoma, Familial 57 40
Lactotroph Adenoma 53 59
Prloma 53 59
Prolactin-Producing Pituitary Gland Adenoma 53
Prolactinoma of Pituitary Gland 12
Familial Prolactinoma 12
Pspa 75

Characteristics:

Orphanet epidemiological data:

59
prolactinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (United Kingdom),6-9/10000 (Belgium),1-5/10000 (Switzerland),1-9/100000 (Malta); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
familial tendency independent of association with men-1


Classifications:



Summaries for Pituitary Adenoma, Prolactin-Secreting

NIH Rare Diseases : 53 Prolactinoma is a tumor of the pituitary gland that causes increased levels of the hormoneprolactin. This hormone normally stimulates breast development and milk production in women. Prolactinoma can affect men or women. In women, the symptoms may include unusual milk production (galactorrhea) when not pregnant or nursing and having no menstrual cycles (amenorrhea). In men, the most common symptoms are decreased sex drive and infertility. Most prolactinomas occur by chance (sporadically) in people with no family history. In a small number of cases, prolactinoma may be caused by a genetic condition such as multiple endocrine neoplasia type 1 (MEN1) or familial isolated pituitary adenoma. Treatment for prolactinoma usually involves taking oral medications known as dopamine agonists. These medications can reduce prolactin levels and shrink the tumor. In more severe cases, radiation therapy or surgery may be needed.

MalaCards based summary : Pituitary Adenoma, Prolactin-Secreting, also known as prolactinoma, is related to prolactin producing pituitary tumor and pituitary adenoma 1, multiple types. An important gene associated with Pituitary Adenoma, Prolactin-Secreting is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include pituitary and t cells, and related phenotypes are male hypogonadism and hypogonadotrophic hypogonadism

OMIM : 57 Prolactin-secreting pituitary adenoma, or prolactinoma, is the most common type of hormonally active pituitary adenoma. These tumors can also be seen as a feature of multiple endocrine neoplasia type I (MEN1; 131100). See also 102200 for a discussion of familial isolated pituitary adenoma (FIPA) and acromegaly due to a growth hormone (GH; 139250)-secreting pituitary adenoma, which are also caused by mutation in the AIP gene. Schlechte (2003) discussed prolactinoma in general terms as a clinical, diagnostic, and therapeutic problem. (600634)

UniProtKB/Swiss-Prot : 75 Prolactin-secreting pituitary adenoma: Most common type of hormonally active pituitary adenoma.

Related Diseases for Pituitary Adenoma, Prolactin-Secreting

Diseases related to Pituitary Adenoma, Prolactin-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 32.4 DRD2 PRL SST
2 pituitary adenoma 1, multiple types 31.3 AIP GH1 IGF1 PRL SST
3 hyperprolactinemia 31.0 DRD2 GH1 IGF1 POMC PRL SST
4 carney complex variant 29.6 AIP GNAS MEN1 POMC PRKAR1A
5 adenoma 27.4 AIP GH1 GNAS IGF1 MEN1 POMC
6 silent pituitary adenoma 11.0 AIP MEN1
7 null pituitary adenoma 11.0 AIP MEN1
8 familial isolated pituitary adenoma 10.8 AIP CDH23
9 fibrous dysplasia/mccune-albright syndrome 10.8 GH1 PRL
10 generalized resistance to thyroid hormone 10.8 PRL TRH
11 bronchus adenoma 10.8 POMC SST
12 pancreatic gastrinoma 10.8 MEN1 SST
13 type c thymoma 10.7 SST SSTR2
14 pancreatic somatostatinoma 10.7 MEN1 SST
15 pituitary apoplexy 10.7 AIP POMC PRL
16 gigantism 10.6 AIP GH1 PRL
17 schizophreniform disorder 10.6 DRD2 PRL
18 chiasmal syndrome 10.6 POMC PRL SST
19 non-functioning pituitary adenoma 10.6 GH1 SST
20 nelson syndrome 10.6 POMC PRL SST
21 lymphocytic hypophysitis 10.6 GH1 POMC
22 carcinoid tumors, intestinal 10.6 MEN1 SST SSTR2
23 hypothalamic disease 10.6 GH1 POMC PRL
24 amenorrhea 10.5 POMC PRL TRH
25 galactorrhea 10.5 DRD2 IGF1 PRL
26 serotonin syndrome 10.5 MEN1 SST SSTR1
27 pancreatic endocrine carcinoma 10.5 SSTR2 SSTR5
28 carcinoid syndrome 10.5 IGF1 MEN1 SST
29 acidophil adenoma 10.4 IGF1 POMC SST
30 sheehan syndrome 10.4 IGF1 POMC PRL
31 central nervous system organ benign neoplasm 10.4 IGF1 POMC PRL
32 pneumonia 10.4
33 pituitary-dependent cushing's disease 10.4 POMC PRL SST TRH
34 oncogenic osteomalacia 10.4 SSTR1 SSTR3 SSTR5
35 sella turcica neoplasm 10.4 POMC PRL
36 endocrine pancreas disease 10.4 IGF1 POMC SST
37 adenohypophysitis 10.4 GH1 POMC PRL TRH
38 hyperandrogenism 10.4 IGF1 POMC PRL
39 opiate dependence 10.4 DRD2 IGF1 POMC
40 tsh producing pituitary tumor 10.3 CDH23 GH1 PRL SST
41 multiple endocrine neoplasia, type iv 10.3 AIP MEN1 PRKAR1A PRL
42 pituitary carcinoma 10.3 POMC PRL SST SSTR2
43 pancreas disease 10.3 IGF1 POMC SST
44 chromophobe adenoma 10.3 GH1 POMC PRL TRH
45 glucose metabolism disease 10.3 IGF1 POMC SST
46 ectopic cushing syndrome 10.3 MEN1 POMC SST SSTR1
47 primary hyperparathyroidism 10.3 MEN1 PRKAR1A PRL
48 endocrine gland cancer 10.3 GNAS MEN1 SST
49 suprasellar meningioma 10.3 POMC TRH
50 gonadal disease 10.2 GH1 IGF1 POMC

Graphical network of the top 20 diseases related to Pituitary Adenoma, Prolactin-Secreting:



Diseases related to Pituitary Adenoma, Prolactin-Secreting

Symptoms & Phenotypes for Pituitary Adenoma, Prolactin-Secreting

Symptoms via clinical synopsis from OMIM:

57
Oncology:
prolactinoma
prolactin-secreting pituitary adenoma


Clinical features from OMIM:

600634

Human phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

59 32 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 male hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000026
2 hypogonadotrophic hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000044
3 amenorrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0000141
4 female hypogonadism 59 32 hallmark (90%) Very frequent (99-80%) HP:0000134
5 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
6 progressive visual loss 59 32 frequent (33%) Frequent (79-30%) HP:0000529
7 blindness 59 32 occasional (7.5%) Occasional (29-5%) HP:0000618
8 diplopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000651
9 gynecomastia 59 32 frequent (33%) Frequent (79-30%) HP:0000771
10 impotence 59 32 hallmark (90%) Very frequent (99-80%) HP:0000802
11 delayed puberty 59 32 occasional (7.5%) Occasional (29-5%) HP:0000823
12 growth hormone excess 59 32 occasional (7.5%) Occasional (29-5%) HP:0000845
13 decreased fertility in females 59 32 hallmark (90%) Very frequent (99-80%) HP:0000868
14 osteopenia 59 32 frequent (33%) Frequent (79-30%) HP:0000938
15 osteoporosis 59 32 frequent (33%) Frequent (79-30%) HP:0000939
16 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
17 sudden loss of visual acuity 59 32 occasional (7.5%) Occasional (29-5%) HP:0001117
18 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
19 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
20 vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002013
21 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
22 hypotension 59 32 frequent (33%) Frequent (79-30%) HP:0002615
23 decreased circulating acth level 59 32 frequent (33%) Frequent (79-30%) HP:0002920
24 easy fatigability 59 32 frequent (33%) Frequent (79-30%) HP:0003388
25 cranial nerve vi palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0006897
26 fourth cranial nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0007011
27 internal ophthalmoplegia 59 32 occasional (7.5%) Occasional (29-5%) HP:0007942
28 secondary growth hormone deficiency 59 32 frequent (33%) Frequent (79-30%) HP:0008240
29 pituitary hypothyroidism 59 32 frequent (33%) Frequent (79-30%) HP:0008245
30 abnormality of hair density 59 32 frequent (33%) Frequent (79-30%) HP:0011357
31 adrenocorticotropin deficient adrenal insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0011735
32 adrenocorticotropic hormone deficiency 59 32 frequent (33%) Frequent (79-30%) HP:0011748
33 decreased fertility in males 59 32 hallmark (90%) Very frequent (99-80%) HP:0012041
34 oculomotor nerve palsy 59 32 occasional (7.5%) Occasional (29-5%) HP:0012246
35 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
36 decreased female libido 59 32 hallmark (90%) Very frequent (99-80%) HP:0030018
37 dyspareunia 59 32 frequent (33%) Frequent (79-30%) HP:0030016
38 bitemporal hemianopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0030521
39 galactorrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0100829
40 hypogonadism 59 Very frequent (99-80%)
41 abnormality of the menstrual cycle 59 Very frequent (99-80%)
42 anterior hypopituitarism 59 Occasional (29-5%)
43 menstrual irregularities 59 Very frequent (99-80%)
44 cranial nerve paralysis 59 Occasional (29-5%)
45 nausea and vomiting 59 Frequent (79-30%)
46 low gonadotropins (secondary hypogonadism) 59 Very frequent (99-80%)
47 central adrenal insufficiency 59 Frequent (79-30%)
48 hemianopsia 59 Occasional (29-5%)
49 abnormality of the pituitary gland 59 Very frequent (99-80%)
50 heteronymous hemianopia 59 Occasional (29-5%)

MGI Mouse Phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 TRHR AIP CDH23 CORT DRD2 GHSR
2 behavior/neurological MP:0005386 10.27 CDH23 CORT DRD2 GHSR GNAS POMC
3 growth/size/body region MP:0005378 10.24 TRHR AIP CDH23 CORT DRD2 GHSR
4 endocrine/exocrine gland MP:0005379 10.22 AIP CORT DRD2 GNAS IGF1 MEN1
5 adipose tissue MP:0005375 10.02 DRD2 GHSR GNAS IGF1 POMC PRKAR1A
6 digestive/alimentary MP:0005381 9.98 DRD2 GHSR MEN1 PRKAR1A SST SSTR2
7 liver/biliary system MP:0005370 9.8 AIP DRD2 GNAS MEN1 POMC PRKAR1A
8 neoplasm MP:0002006 9.76 AIP DRD2 GNAS IGF1 MEN1 POMC
9 nervous system MP:0003631 9.73 PRL PTTG1 SST SSTR1 SSTR2 TRH
10 no phenotypic analysis MP:0003012 9.23 DRD2 GHSR GNAS POMC PTTG1 SST

Drugs & Therapeutics for Pituitary Adenoma, Prolactin-Secreting

Drugs for Pituitary Adenoma, Prolactin-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Central Nervous System Depressants Phase 4
6 Serotonin Agents Phase 4
7 Serotonin Antagonists Phase 4
8 Tranquilizing Agents Phase 4
9 Dopamine Antagonists Phase 4
10 Antipsychotic Agents Phase 4
11 Psychotropic Drugs Phase 4
12
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
13
Cabergoline Approved Phase 2, Phase 3,Not Applicable 81409-90-7 54746
14
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
15 Dopamine agonists Phase 2, Phase 3,Phase 1,Not Applicable
16 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Not Applicable
17 Antiparkinson Agents Phase 2, Phase 3,Phase 1,Not Applicable
18 Hormone Antagonists Phase 2, Phase 3,Phase 1
19 Hormones Phase 2, Phase 3,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Protective Agents Phase 2, Phase 3,Phase 1,Not Applicable
22 Autonomic Agents Phase 2, Phase 3,Phase 1,Not Applicable
23
Bromocriptine Approved, Investigational Phase 2,Not Applicable 25614-03-3 31101
24
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 5095 497540
25
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
26
Enclomiphene Investigational Phase 2 15690-57-0
27
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
28 Clomiphene Phase 2
29 Fertility Agents Phase 2
30 Selective Estrogen Receptor Modulators Phase 2
31 Estrogen Antagonists Phase 2
32 Estrogen Receptor Modulators Phase 2
33 Estrogens Phase 2
34 Zuclomiphene Phase 2
35 Protein Kinase Inhibitors Phase 2
36 Citrate Nutraceutical Phase 2
37
Curcumin Approved, Investigational Phase 1 458-37-7 969516
38
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
39 Analgesics Phase 1,Not Applicable
40 Analgesics, Non-Narcotic Phase 1,Not Applicable
41 Turmeric extract Phase 1
42 Anti-Inflammatory Agents Phase 1,Not Applicable
43 Anti-Inflammatory Agents, Non-Steroidal Phase 1,Not Applicable
44 Antirheumatic Agents Phase 1,Not Applicable
45 Dexamethasone acetate Phase 1 1177-87-3
46 glucocorticoids Phase 1
47
protease inhibitors Phase 1
48 Gastrointestinal Agents Phase 1
49 HIV Protease Inhibitors Phase 1
50 Antiemetics Phase 1

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
2 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
3 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
4 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
5 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
6 Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes Recruiting NCT02544321 Phase 2 Bromocriptine
7 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
8 Temozolomide in Treating Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
9 Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Unknown status NCT01344291 Phase 1 Curcumin
10 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
11 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
12 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Not Applicable Cabergoline;cabergoline
13 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949
14 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Cabergoline
15 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
16 Study on Therapy of Non-invasive Prolactinoma Recruiting NCT03353025 Not Applicable dopamine agonist treatment
17 Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Recruiting NCT02536261
18 Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA Recruiting NCT00461188
19 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
20 PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon Recruiting NCT02854228
21 Rhinological Outcomes in Endonasal Pituitary Surgery Active, not recruiting NCT01504399
22 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Active, not recruiting NCT03043508
23 Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas Not yet recruiting NCT03400865 Not Applicable HCQ/CQ and CAB combined treatment
24 Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma Not yet recruiting NCT03457389 Not Applicable Cabergoline
25 Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma Not yet recruiting NCT03284775 Not Applicable

Search NIH Clinical Center for Pituitary Adenoma, Prolactin-Secreting

Cochrane evidence based reviews: prolactinoma

Genetic Tests for Pituitary Adenoma, Prolactin-Secreting

Anatomical Context for Pituitary Adenoma, Prolactin-Secreting

MalaCards organs/tissues related to Pituitary Adenoma, Prolactin-Secreting:

41
Pituitary, T Cells

Publications for Pituitary Adenoma, Prolactin-Secreting

Articles related to Pituitary Adenoma, Prolactin-Secreting:

(show all 24)
# Title Authors Year
1
Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery. ( 27168837 )
2016
2
Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. ( 25616657 )
2015
3
Lower Prolactin Levels During Cabergoline Treatment are Associated to Tumor Shrinkage in Prolactin Secreting Pituitary Adenoma. ( 25230324 )
2014
4
Pathology quiz case 3: ectopic prolactin-secreting pituitary adenoma. ( 23329101 )
2013
5
Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma. ( 22654846 )
2011
6
Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas. ( 19929252 )
2010
7
Pseudotumor cerebri and prolactin secreting pituitary adenoma. Association or coincidence? ( 20831031 )
2010
8
Cystic mammary adenocarcinoma associated with a prolactin-secreting pituitary adenoma in a New Zealand white rabbit (Oryctolagus cuniculus). ( 18589874 )
2008
9
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. ( 18332900 )
2008
10
SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas. ( 17473207 )
2007
11
Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. ( 16622555 )
2006
12
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. ( 15070915 )
2004
13
A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. ( 11415850 )
2001
14
Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder. ( 10738858 )
2000
15
Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. ( 10401709 )
1999
16
Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. ( 9666865 )
1998
17
Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. ( 8626821 )
1996
18
Pulsatile thyrotropin and prolactin secretion in a patient with a mixed thyrotropin- and prolactin-secreting pituitary adenoma. ( 8130883 )
1994
19
Detection of growth hormone, prolactin and human beta-chorionic gonadotropin mRNA in growth hormone-secreting pituitary adenomas and in prolactin-secreting pituitary adenomas by in situ hybridization using a non-isotopic detection method. ( 8317187 )
1993
20
Light and electron microscopic observation of the same mammosomatotroph cell in a mixed growth hormone- and prolactin-secreting pituitary adenoma--case report. ( 7685856 )
1993
21
Treatment and long-term follow-up results of prolactin secreting pituitary adenomas. ( 1890464 )
1991
22
Effects of naloxone on prolactin-secreting pituitary adenomas. ( 1695330 )
1990
23
Prolactin-secreting pituitary adenoma in a man with gigantism: a case report. ( 394552 )
1979
24
Prolactin-secreting pituitary adenomas. Association with multiple endocrine neoplasia, type I. ( 507096 )
1979

Variations for Pituitary Adenoma, Prolactin-Secreting

ClinVar genetic disease variations for Pituitary Adenoma, Prolactin-Secreting:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 LRP2 NM_004525.2(LRP2): c.13753C> T (p.Arg4585Ter) single nucleotide variant Likely pathogenic rs202057289 GRCh37 Chromosome 2, 169985570: 169985570
2 LRP2 NM_004525.2(LRP2): c.13753C> T (p.Arg4585Ter) single nucleotide variant Likely pathogenic rs202057289 GRCh38 Chromosome 2, 169129060: 169129060

Cosmic variations for Pituitary Adenoma, Prolactin-Secreting:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM771 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 21
2 COSM760 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 21
3 COSM483 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 21
4 COSM482 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 21
5 COSM27887 GNAS pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 21
6 COSM27896 GNAS pituitary,NS,adenoma,GH c.680A>G p.Q227R 20:58909541-58909541 21
7 COSM27899 GNAS pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 21
8 COSM27895 GNAS pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 21
9 COSM27888 GNAS pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 21

Expression for Pituitary Adenoma, Prolactin-Secreting

Search GEO for disease gene expression data for Pituitary Adenoma, Prolactin-Secreting.

Pathways for Pituitary Adenoma, Prolactin-Secreting

GO Terms for Pituitary Adenoma, Prolactin-Secreting

Cellular components related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 AIP CDH23 DRD2 GHSR GNAS IGF1
2 neuron projection GO:0043005 9.35 GHSR SSTR1 SSTR2 SSTR3 SSTR5
3 endosome lumen GO:0031904 9.16 GH1 PRL

Biological processes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 spermatogenesis GO:0007283 9.97 GHSR PTTG1 SSTR1 SSTR2 SSTR3
2 cell-cell signaling GO:0007267 9.93 DRD2 POMC SST SSTR3 TRH
3 chemical synaptic transmission GO:0007268 9.91 CORT SST SSTR3 SSTR5
4 regulation of signaling receptor activity GO:0010469 9.87 CORT GH1 IGF1 POMC PRL SST
5 negative regulation of cell proliferation GO:0008285 9.8 DRD2 MEN1 SST SSTR1 SSTR2 SSTR3
6 glucose homeostasis GO:0042593 9.79 IGF1 POMC SSTR5
7 female pregnancy GO:0007565 9.77 GHSR GNAS PRL
8 forebrain development GO:0030900 9.76 DRD2 SSTR1 SSTR2 SSTR3
9 response to nutrient levels GO:0031667 9.74 GH1 IGF1 PRL
10 cerebellum development GO:0021549 9.73 SSTR1 SSTR2 SSTR3
11 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.73 SSTR1 SSTR2 SSTR3 SSTR5
12 G-protein coupled receptor signaling pathway GO:0007186 9.73 CORT DRD2 GHSR GNAS POMC SST
13 response to starvation GO:0042594 9.7 SSTR1 SSTR2 SSTR3
14 cellular response to estradiol stimulus GO:0071392 9.69 SSTR1 SSTR2 SSTR3
15 positive regulation of multicellular organism growth GO:0040018 9.67 DRD2 GH1 GHSR
16 cellular response to glucocorticoid stimulus GO:0071385 9.65 SSTR2 SSTR3 SSTR5
17 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 PRL
18 positive regulation of growth GO:0045927 9.59 GH1 GHSR
19 peristalsis GO:0030432 9.58 DRD2 SSTR2
20 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 GH1 GHSR IGF1
21 hormone-mediated apoptotic signaling pathway GO:0008628 9.55 SST SSTR3
22 neuropeptide signaling pathway GO:0007218 9.55 POMC SSTR1 SSTR2 SSTR3 SSTR5
23 somatostatin signaling pathway GO:0038170 8.92 SSTR1 SSTR2 SSTR3 SSTR5
24 signal transduction GO:0007165 10.11 DRD2 GHSR GNAS IGF1 POMC SSTR1

Molecular functions related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.91 DRD2 GHSR SSTR1 SSTR2 SSTR3 SSTR5
2 G-protein coupled receptor binding GO:0001664 9.58 CORT GNAS POMC
3 peptide binding GO:0042277 9.56 SSTR1 SSTR2 SSTR3 SSTR5
4 neuropeptide binding GO:0042923 9.46 SSTR1 SSTR2 SSTR3 SSTR5
5 insulin-like growth factor receptor binding GO:0005159 9.43 GNAS IGF1
6 prolactin receptor binding GO:0005148 9.32 GH1 PRL
7 somatostatin receptor activity GO:0004994 9.26 SSTR1 SSTR2 SSTR3 SSTR5
8 hormone activity GO:0005179 9.17 CORT GH1 IGF1 POMC PRL SST

Sources for Pituitary Adenoma, Prolactin-Secreting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....